Arbutus Biopharma Corp
Sector: Manufacturing
Industry: Pharmaceutical Products
3.35
0.12
(3.72%)
Volume:
834,314
52 week range:
2.71 - 4.73
Market Cap:
618.481M
Company Description:
Arbutus Biopharma Corporation develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate. AB-836, an oral capsid inhibitor that suppresses HBV DNA replication, is in Phase Ia/Ib clinical trial targeted to hepatocytes.